Cargando…

Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity

Detalles Bibliográficos
Autor principal:	Hindson, Jordan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923332/ https://www.ncbi.nlm.nih.gov/pubmed/35292751 http://dx.doi.org/10.1038/s41575-022-00603-z

Ejemplares similares

Investigating two versus three doses of mRNA vaccine in patients with cirrhosis
por: Hindson, Jordan
Publicado: (2022)

Intelligent and autonomous magnetic endoscopy
por: Hindson, Jordan
Publicado: (2020)

SARS-CoV-2 in patients with chronic liver disease
por: Hindson, Jordan
Publicado: (2020)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

COVID-19: faecal–oral transmission?
por: Hindson, Jordan
Publicado: (2020)

Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care
por: Barnes, Alex, et al.
Publicado: (2022)

COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)
por: Kubas, Aleksandra, et al.
Publicado: (2022)

The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients
por: Higgins, Peter D R, et al.
Publicado: (2020)

Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients
por: Spencer, Elizabeth A, et al.
Publicado: (2021)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

IBD in the Time of COVID19
por: Moss, Alan, et al.
Publicado: (2020)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
por: Pasikhova, Yanina, et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD
por: Demase, Kathryn, et al.
Publicado: (2023)

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
por: Ray, Katrina
Publicado: (2021)

Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
por: Cotugno, Nicola, et al.
Publicado: (2022)

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
por: Graham, Simon P., et al.
Publicado: (2020)

Prevention of COVID-19 in patients with IBD
por: Segal, Jonathan P, et al.
Publicado: (2020)

Managing IBD in the COVID-19 era
por: Scalzo, Nicholas, et al.
Publicado: (2023)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients
por: Havlin, Jan, et al.
Publicado: (2021)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2020)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic
por: Mastronardi, Mauro, et al.
Publicado: (2020)

The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report
por: Damirchi, Mohammadrafi, et al.
Publicado: (2023)

Patients with IBD have a more cautious attitude towards COVID-19 vaccination
por: Hu, Shurong, et al.
Publicado: (2023)

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine
por: Toh, Zheng Quan, et al.
Publicado: (2020)

Repurposing metabolic drugs for COVID-19
por: Bordon, Yvonne
Publicado: (2023)

Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients
por: Papa, Alfredo, et al.
Publicado: (2021)

Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine
por: Wang, Ying, et al.
Publicado: (2020)

Trilogy of COVID-19: Infection, Vaccination, and Immunosuppression
por: Mohanraj, Dinesh, et al.
Publicado: (2022)

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
por: Shirai, Shimpei, et al.
Publicado: (2018)

Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
por: Vollenberg, Richard, et al.
Publicado: (2023)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uj8nm1d606q5urchjea644mqo9